{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:59:30Z","timestamp":1762102770556,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["STRATEGMED2\/265566\/6\/NCBR\/2015"],"award-info":[{"award-number":["STRATEGMED2\/265566\/6\/NCBR\/2015"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>TRAIL (TNF-related apoptosis inducing ligand) exhibits selective proapoptotic activity in multiple tumor types, while sparing normal cells. This selectivity makes TRAIL an attractive therapeutic candidate. However, despite encouraging activity in preclinical models, clinical trials with TRAIL mimetics\/death receptor agonists demonstrated insufficient activity, largely due to emerging resistance to these agents. Herein, we investigated the cytotoxic activity of a novel, TRAIL-based chimeric protein AD-O51.4 combining TRAIL and VEGFA-derived peptide sequences, in hematological malignancies. We characterize key molecular mechanisms leading to resistance and propose rational pharmacological combinations sensitizing cells to AD-O51.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sensitivity of DLBCL, classical Hodgkin lymphoma, (cHL), Burkitt lymphoma (BL) and acute myeloid leukemia (AML) to AD-O51.4 was assessed <jats:italic>in vitro<\/jats:italic> with MTS assay and apoptosis tests (Annexin V\/PI staining). Markers of apoptosis were assessed using immunoblotting, flow cytometry or fluorogenic caspase cleavage assays. Resistant cell lines were obtained by incubation with increasing doses of AD-O51.4. Transcriptomic analyses were performed by RNA sequencing. Sensitizing effects of selected pathway modulators (BCL2, dynamin and HDAC inhibitors) were assessed using MTS\/apoptosis assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AD-O51.4 exhibited low-nanomolar cytotoxic activity in DLBCL cells, but not in other lymphoid or AML cell lines. AD-O51.4 induced death-receptor (DR) mediated, caspase-dependent apoptosis in sensitive DLBCL cells, but not in primary resistant cells. The presence of DRs and caspase 8 in cancer cells was crucial for AD-O51.4-induced apoptosis. To understand the potential mechanisms of resistance in an unbiased way, we engineered AD-O51.4-resistant cells and evaluated resistance-associated transcriptomic changes. Resistant cells exhibited changes in the expression of multiple genes and pathways associated with apoptosis, endocytosis and HDAC-dependent epigenetic reprogramming, suggesting potential therapeutic strategies of sensitization to AD-O51.4. In subsequent analyses, we demonstrated that HDAC inhibitors, BCL2 inhibitors and endocytosis\/dynamin inhibitors sensitized primary resistant DLBCL cells to AD-O51.4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taken together, we identified rational pharmacologic strategies sensitizing cells to AD-O51.4, including BCL2, histone deacetylase inhibitors and dynamin modulators. Since AD-O51.4 exhibits favorable pharmacokinetics and an acceptable safety profile, its further clinical development is warranted. Identification of resistance mechanisms in a clinical setting might indicate a personalized pharmacological approach to override the resistance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1048741","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T06:22:10Z","timestamp":1667197330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Karolina","family":"Piechna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"\u017bo\u0142yniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Noyszewska-Kania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Szyd\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart\u0142omiej","family":"\u017berek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kulecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Rumie\u0144czyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Juszczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/35037747","article-title":"From bench to clinic with apoptosis-based therapeutic agents","volume":"407","author":"Nicholson","year":"2000","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.214","article-title":"Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways","volume":"4","author":"van Dijk","year":"2013","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s10637-016-0420-1","article-title":"First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors","volume":"35","author":"Forero","year":"2017","journal-title":"Invest New Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605507","article-title":"Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer","volume":"102","author":"Trarbach","year":"2010","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","article-title":"Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer","volume":"61","author":"Greco","year":"2008","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large b cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse Large b cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large b-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large b-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse Large b-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-b-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32845","article-title":"Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance","volume":"147","author":"Rozga","year":"2020","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611399104","article-title":"Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large b cell lymphomas","volume":"104","author":"Polo","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK inhibition modulates distinct PI3K\/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse Large b cell lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1023","article-title":"Inhibition of PIM kinases in DLBCL targets MYC transcriptional program and augments the efficacy of anti-CD20 antibodies","volume":"81","author":"Szyd\u0142owski","year":"2021","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-020-03156-8","article-title":"Serine biosynthesis pathway supports MYC\u2013miR-494\u2013EZH2 feed-forward circuit necessary to maintain metabolic and epigenetic reprogramming of Burkitt lymphoma cells","volume":"12","author":"Bia\u0142opiotrowicz","year":"2020","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S307305","article-title":"Multi-organ transcriptome dynamics in a mouse model of cecal ligation and puncture-induced polymicrobial sepsis","volume":"14","author":"Rumienczyk","year":"2021","journal-title":"J Inflammation Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an r package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS: A J Integr Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41419-020-03156-8","article-title":"SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism","volume":"11","author":"Polak","year":"2020","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.90","article-title":"TRAIL induces necroptosis involving RIPK1\/RIPK3-dependent PARP-1 activation","volume":"19","author":"Jouan-Lanhouet","year":"2012","journal-title":"Cell Death Differ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.389","article-title":"Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in b-cell hematologic malignancies","volume":"4","author":"Marconi","year":"2013","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2217\/epi-2017-0112","article-title":"The bitter side of epigenetics: variability and resistance to chemotherapy","volume":"13","author":"Hajji","year":"2021","journal-title":"Epigenomics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062917-012644","article-title":"Regulation of clathrin-mediated endocytosis","volume":"87","author":"Mettlen","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.3390\/ijms22063160","article-title":"Cytotoxic efficacy and resistance mechanism of a TRAIL and VEGFA-peptide fusion protein in colorectal cancer models","volume":"22","author":"Kopczynski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00071","article-title":"Get a ligand, get a life: Integrins, signaling and cell survival","volume":"115","author":"Stupack","year":"2002","journal-title":"J Cell Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.234","article-title":"Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines","volume":"6","author":"Polanski","year":"2015","journal-title":"Cell Death Disease"},{"key":"B34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1593\/neo.04688","article-title":"Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line","volume":"7","author":"Zhang","year":"2005","journal-title":"Neoplasia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1048741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T06:22:12Z","timestamp":1667197332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1048741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":34,"alternative-id":["10.3389\/fonc.2022.1048741"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1048741","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"article-number":"1048741"}}